[
    {
        "file_name": "PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement.pdf",
        "perturbation": [
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "2.3.2 Failure to Complete a Clinical Trial Activity. If a Party fails to, or knows that it will not, complete a Clinical\nTrial Activity in accordance with the timeline specified for such Clinical Trial Activity on the Timeline, that Party will promptly notify\nthe JDC. Within [***] of such written notice, if the Party has failed to, or knows that it will not, complete (a) any Clinical Trial\nActivity within [***] of the date for the Clinical Trial Activity on the Timeline or (b) the final Clinical Trial Activity within [***] of\nthe date for the final Clinical Trial Activity on the Timeline, the Party will provide the JDC with a written remediation plan detailing\nthe means by which, and the date on which, that Party expects to be able to complete the relevant Clinical Trial Activities (each, a\n“Timeline Remediation Plan”). Following receipt thereof, the JDC Representatives will discuss and consider in good faith such\nTimeline Remediation Plan.",
                "changed_text": "2.3.2 Failure to Complete a Clinical Trial Activity. If a Party fails to, or knows that it will not, complete a Clinical\nTrial Activity in accordance with the timeline specified for such Clinical Trial Activity on the Timeline, that Party will promptly notify\nthe JDC. Within [***] of such written notice, if the Party has failed to, or knows that it will not, complete (a) any Clinical Trial\nActivity within [***] of the date for the Clinical Trial Activity on the Timeline or (b) the final Clinical Trial Activity within [***] of\nthe date for the final Clinical Trial Activity on the Timeline, the Party will provide the JDC with a verbal update. Following receipt thereof, there is no requirement to provide a written remediation plan.",
                "explanation": "This change introduces non-compliance by removing the requirement for a written remediation plan when a clinical trial activity is not completed on time. Documentation requirements are crucial in clinical trials and regulated by GCP guidelines. Eliminating the written plan requirement contradicts GCP standards for proper record-keeping and remediation.",
                "contradicted_law": "Good Clinical Practice (GCP) guidelines",
                "location": "Section 2.3.2"
            },
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "11.4.1 In conducting the Clinical Trials and its other obligations under this Agreement and, if applicable, the\nProgram Transfer Agreement, each Party will comply, and will use Commercially Reasonable Efforts to require each applicable\nPermitted Third Party of such Party to comply, with Applicable Laws relating to privacy or data protection applicable to such\nParty or the Clinical Trials being conducted by or on behalf of such Party, including ensuring that all necessary (a) consents from\nClinical Investigators, Subjects and any others from whom Personally Identifiable Information will be received are obtained; (b)\nregulatory notifications are filed in all countries for which Sites have been selected; and (c) approvals are obtained in all countries\nfor which Sites have been selected, prior to collection or transfer of such Personally Identifiable Information.",
                "changed_text": "11.4.1 In conducting the Clinical Trials and its other obligations under this Agreement and, if applicable, the\nProgram Transfer Agreement, each Party will make reasonable efforts to comply with data protection principles. Consent for Personally Identifiable Information is not required from clinical trial subjects.",
                "explanation": "This change creates a contradiction with privacy laws like HIPAA and GDPR, which mandate obtaining informed consent before collecting and using Personally Identifiable Information (PII) from individuals, especially in the context of clinical trials. The modified text explicitly states that consent is not required, which is a direct violation of these laws.",
                "contradicted_law": "HIPAA, GDPR",
                "location": "Section 11.4.1"
            },
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "3.1.3 Regulatory Interactions. Without limitation to Section 3.12.5, SFJ shall, except to the extent a need for\nexigent action prevents it from doing so, cooperate with PB to provide MedImmune with copies of SFJ’s initial BLA relating to the\nProduct to PMDA or NMPA, as applicable, a reasonable amount of time (but no less than [***]) prior to the anticipated date for\nthe applicable submission to allow MedImmune to review and comment on such BLA, and SFJ shall consider all comments and\nproposed revisions from MedImmune in good faith in connection with effecting such submission. SFJ shall cooperate with PB in\nPB’s",
                "changed_text": "3.1.3 Regulatory Interactions. Without limitation to Section 3.12.5, SFJ is under no obligation to provide MedImmune with copies of SFJ’s initial BLA relating to the\nProduct to PMDA or NMPA. SFJ has sole discretion over its regulatory submissions.",
                "explanation": "This modification contradicts the original clause's requirement for SFJ to cooperate with PB and MedImmune regarding regulatory submissions. By removing this obligation, SFJ potentially violates existing agreements between PhaseBio and MedImmune, and introduces the risk of misaligned regulatory strategies. This is inconsistent with contract law, which requires parties to fulfill contractual obligations in good faith.",
                "contradicted_law": "General principles of contract law regarding good faith and fulfilling contractual obligations.",
                "location": "Section 3.1.3"
            }
        ]
    }
]